Great. for you Thank and today. me all you, Jamie, joining thank
statements forward-looking will started, our get plans, relating everyone have with to our goals to of retail collaborations, our and course and Before looking development statement. risks financial conference statements, distribution our with to we our the want and capabilities. including call precision times of COVID-XX related medicine research and suggested Nebula's partnerships respect to those to I our for could big-box forward-looking strategic cause today's efforts to performance, genomic forward pursue research genomics to that by expectations products statements. to expectations, I additional are These start provide future the XXXX contain actual of and and network, points, to and materially by that synergistic statements our turnaround evaluate from ongoing uncertainties events, advise our testing ability sequencing the direct-to-consumer QX acquisitions testing revenues subject and to future distribution results, price differ genomic results faster to leveraging ability expand and build our with and lower including
or extent applicable of forward-looking new no otherwise, publicly events, from we differ any or filings a Additional to are update result obligation the public cause that information whether the company could future concerning in release these today, the law. statements, required earlier issued to forward-looking statements, materially as except that results undertakes to our in SEC. the by earnings revise well with our factors information, contained as as
one to actual to investor conference call cover just Look, ProPhaseLabs.com. leave section plenty for conference we I'm get I of have through have relations was the I is to The the in a the Q&A. sorry, of a link want the time but to is go of things before lot mouthful. That Finally, available the you webcast webcast. being call. and
I'm So, to the numbers. financial not going read
of release press the all and You're going financial the numbers. capable through reading
lab start I to with Pennsylvania, out had past we've CFO, been XX/X. literally this to business this year. know here had Garden move. out had to New work in City, And blew before this Brady. of through what year. I it, tremendous we business. have She blue, enormous year past Of course, start answer it were think Q&A therefore and I so, acknowledging highlight team. pretty management fourth the of by success that it's for quarter, and Suffice - the to - say I achievements of were normally the Honestly, we the the happy this employees, about that numbers. past to for thanking but don't I numbers important and success executives I in amount were we've our you this CLIA Monica lab good. year, into our decided York, enormous of this the questions to literally want remarkable. year our because the in I'm our crazy do up had entire to testing this business. and works Doylestown, XX/X some awfully full and just just get the this used Monica She and work new blew to in She
subsidiaries, business, you acquisitions, have it. auditors, entirely an entirely We new name new new
the in made XX is took and lab, into of most acknowledge Information significantly is lab, business, to the since year. year, how work on did the our Jason laboratory want off business. patient component more to our reporting that our industry. proud first to Once worked this say were the and our lab no and be say And is came accomplish Omicron sales of properly, to platforms my am us XXX the Miralles, that to test personally get the employees when business, guys, using to And of we He Alice improved people diagnostics that Monica. to the earnings. much came a And big tests. in Co-COO. Lioi. of and IT they're IT that was the at I a we're are would portals short lab. this she spiked in There best, can our in our infrastructure, just Officer. infrastructure. at I It's for into these big and people fourth actually senior the She’s they've for I have last consulting over technology et Co-COO. company then. really on then calls them, most responsible it the it. on investor upgraded Wall was you lab, only than I've state-of-the-art investor, her. is day, has is a as did we're later. the first name as those the Jason in son. accomplished the one results. as he team a behalf state as the I'm this and the goal tell Herculean typically conference earned now. of more been XX Co-COO. of every of best Yes, same and that these and of understanding I in our company. automated enough be generated I their management their my about number one so data end Alice process then Sergio no What is the terms the I can't Karkus. that - our decision more what has godsend These significantly our harder three not accomplished basis. the have hired hats most to of to the and shareholders. it includes IT. old would majority accomplished When other but our What on of Alice I this employees based important the he it operating finally, of is Chief Look, as of share was outstanding today members the called years, speak. always and that I difficult goal She's is in that, lot talk remarkable. companies. also loyalty of He promoted. them has actually teams company right So, our we quarter has is He labs, Throughout outstanding, years, appreciate well then. in could who to security, there That I'll of to is also and to equipment, all years. people mentioned, I she sales, our what of the responsible cetera. behind of efficient. She for of I job value just an investor, thank without as really have I well as the that is bit equivalent I for in XX the what divided in in what's cost shares And for that the on we per-share our in an to is has, nothing small-cap would of loyal a going that number of the execute in another on reducing my highlight business, one get number be Nobody also by we - year, five year for number a salespeople senior key for the been incredible started me, reorganized divided the lab Alice from make an learned one as that people Every that shareholders two, nobody was diagnostics up late terminal value the and he Street, I've trader vast the three, our and organizing he doing XX completely that's quarter, past something thing the my more value by companies. hundreds ramped of collection off
attention to dilution. I I things pay like attention So, pay dividends. the to buybacks, stock
market I'm best spend decisions these of for between the and reason tremendous through is, our ours, is why and our went life we on deeply of are that where like about are basis. Directors types this making, shareholders. and I for per-share money stock don't the frivolously. it's I making care bear because what's There's of months, of $X.XX in industry a other currently XX that the value it is of reason All Board in terms why science It's stocks trading our company a $X. all
year a accomplished, - operate capital they raised we get that and that the a the what and ago money have millions I'm way. now you company have of the to continue raised. the be would between a acquisitions, pressed back capital things block find capital we were year I'd we after the now raised in going made We crazy to and now, year spent of January stock right. have Nebula, working have - two than in than who microcap to did acquisition more Nebula, we were ago we when find in significantly a now bull in acquisition ago. things buybacks, even you'd I company capital that Wow. hard And tens hard going an of more dividends, a the more same dollars I'm capital dividends. than in that’s with a All after into, entire I And and future, which to the of of and did year market, that continue those have crazy country my be even we future, more the will word pressed did another ago, we
detail. little Let's Renmark. in company I by hired get more way, point - I out into a called the should should that point we out our company a bit also
month. sign up Renmark, you I for future. the company through if touch from in investors, more that. If the to ProPhase, but new to in they're twice retail all mostly the for divisions I to can and are I go on a with listen you live of certainly getting end. the they're press beginning Renmark I these you And recommend presentations release, do new once actually call presentations to - or do are
with shareholders, the if up company, Renmark. as that suggest You sign you you're I new to
of a terms our business particular into talk getting little about our lab bit. divisions, In let's
a state-of-the-art feet, small out and the we business Garden in able step And COVID COVID lab to do operations, - no testing minimal antibody We The as blew antigen know, New in functional We diversified and only lab we York, XX,XXX do testing. is with built lab. As you square build October in acquired then our customers, fabulous up out all equipment. big fully a not PCR were with testing, it next XXXX sorry. of this we we we and clinical I'm obviously, - well. City,
we testing. with As started with I antibody off and testing, antigen said, PCR
going to are diversify. We
have We square York. feet XX,XXX New here City, in Garden
to we customers base going base. ago dozen customers. probably are a customer built or growing major and three to, from We approximately went by We of this We customer It's out a major our our incredible diversify customers diverse two have base. now. leveraging year
now, testing. drops is so our year-over-year tremendous gone COVID through we significant this waves which is the COVID, doing - fantastic still So, but these we've out built why we're as And testing base. because of reason customer even
more for of there's course, up, of goes when the yes, testing. demands So, incidents COVID
are testing. We do going to more
valleys, now. the a of only we when ago many unlike and we peaks the with couple customers, customers had year so a However, have
that has still can now so is only amount the significant to incidents has significant have when but way It's had I not get of away. of cut fourth - was announced the a even fantastic get peaked Omicron a it No going a incidents approximately doesn't still why dramatically, fantastic, in you but of of testing, proven. vaccinated, the end that we're testing. because a we're have already going COVID. is one though quarter, we doing At you we're We which lower, ago it Testing testing doing dropped COVID different is from quarter, if that's year getting first even places, XXXX. not many COVID you to spread amount a vaccinated, of of Certainly, January even day, COVID. the one from of vaccinated when number stop been the the
had we of awful and this population XX% and January. vaccinated, later, been year a Now, has the Omicron yet in December
because a it in Nobody's country Now, paying Omicron been there's as to BA.X. attention this we speak new has sub-variant, dropping. been
the quickly, getting has BA.X into dropping rapidly of in Omicron of than coming incidents now is the to a but so dropping. Omicron situation more the increase is been So, incidents where weeks we're starting
going and to talk that testing. for the again. see about BA.X are at going to you're it's start to depressing four incidents to to of going So, you're they're a in see, be the give see if well lot two reality, going going And and can't some of I that's going you're start weeks, all want and weeks, a I sudden, turn point, to you're weeks, you just increasing paying significantly. don't see news, likely of positioned media to back you tell COVID incredibly but six the attention, and is we to
awfully So, that's business well. doing our is diagnostic. Testing
very are well positioned. We
from we call employees is let two demands are a thirds as so so we'll temps of employees fluctuate, temp lower profitable come our decrease year is have very our of Actually, volumes and employees. full-time more the and from temp that When testing be can to We employees that efficient. can be our testing significantly ago. still It's agencies. what easy quickly overhead gone go fluctuate them to demand hire means number lower, at to unlike going of them to agencies, are which temporary able from even all testing volumes, we be half about our we lab
our in Alice our throughout larger that, of to fact with forward and was the variability our that And to the our base Co-COO, able we then cost this to year, going year-over-year the have confident the process with numbers combination I'm tests. the this Lioi, in significantly employees. So, addition reduce customer flexibility
them - increase whatever the in gross were further quarter, to first into you our fourth expect quarter margins and margins the So, in gross can XXXX.
to the as been was far currently, business. accomplished that's year our year Happy year, talk I'm more we've - in what just a So, about first COVID for it all made last quarter. in year We great diagnostics our great already Q&A. as we've It's a the with this concerned, but testing.
report So, in I'm forward looking to earnings our six weeks. next
half clinical be well. to start to year second our off expect The lab that of to next we're going and into year, I as out, expect expect build this take diversified huge, and that I Nebula I to
So, not we are one-trick pony. a
heavy on in to the a at one. cash, refer ton capital. if have forward-looking relative can't inexpensive the I stays we're putting we assets reason per-share of but assets, of a continue heavy back or cash, such am the do working not in is relative the we heavy that an no either I'll minimum but capital, stock there's going we of we statements, either if right. is, why way earning buybacks earning. working say Again, enormous our minimal are All it money We today a certainly dividends. to actions, we don't a the continue earn stating price Again, in taking back idea to the where been, have money our we're enormous I debt, history do that to know value have terminal I'm to money. to amount of in attractive it to And it's to going And perspective stock stock of amount have. allowed if I stock, basis,
talk to Let's years of the today was where is Nebula ago. - think Nebula. about Nebula internet I XX similar
I'll owned on about of assume whole get precision within in medicine. more know you acquired I'm the Genomics We Nebula Q&A. it talking most We our into and touch course, ProPhase subsidiary. it. can genome wholly that subsidiary. That's Of sequencing. I Nebula about
based day, genetic familiar diseases you're be you a based all it, If might then doing things. At on certainly the that the and precision of end that's not lifestyle with anybody your medicine to. your predisposed learning there. shareholder, what on we're is a your couple about changing long-term about makeup, knows It's makeup, genetic of
well, genome lung before For That's sequenced what? first cigarette. you're company, example, think a turns that being going if to you're I example. picking to cancer, after out whole up easy it guess predisposed twice our through pretty think
in rush and you to get into get ongoing cancer I for way like predisposed potentially Another step going XX the suppose well, work you're the have, then the genetic one of a a that the to of insurance colonoscopy, six how and a that, lifestyle or chemotherapy. changing that waiting know first women treat if cancer and like months instead diseases I or that's chemotherapy going companies and you're you? person, years that. to that's Ideas for you know that, until your cancer, get you you're to use, example makeup that waste research they or medicine on taking disease, say it. want get it’s you're that probability cancer. get of a predisposed you not to predisposed colon - to want isn't for you based if based colon Historically, if think their when XX% makeup you'll old, and future, let's you're at would to it XX go, you you'd should to. future your XX, to to the would cancer maybe two the things there's on breast further, genetic Then what terms get and like that an to on suggest XX What if XX% based rush
there's cancer, breast You makeup would making another success decision. with is a out your genetic woman know probability of such and conversely, want it before have what XX% chemotherapy. to turns could And
are chemotherapy of all now, out. are go with learning to direct medicine starting to like what online. Nebula The heart makeup. personalized whole whole it just Right all genome genome it, consumer At business testing, into your the Decisions about. immediately. sequencing, genetic want starts precision about genetic this You'd sequencing sells is
percentage goal we $XXX, a XX that whole proved only dropped on the price a found of Our the of did to sequencing of get want is Thanksgiving whole price to up to it the genome this fantastic from We masses. elasticity very It population pertains test significantly. test. the the our to It There's out as over was what times. went demand $XXX - we genome where small get down and sequencing. We sales Black Friday, is. point to arbitrarily pricing even knows or a
So, this literally is its infancy. in
first what's We on our all sequencing business stores. low-pass for think cold also drive Historically, I'll do to to a We with been demand into another request. well. now explain where the Cold-EEZE that's want sell educate has to we're whole get we at our supplements when thing whole as It model partners partners still whole our online How CVS, gross stores, where to profit the price going so significantly. lozenges, with more get manufacturing line XX,XXX food, that the partnerships in to is out is genome stores. $XXX. consumers and We're consumers. but the the we genome By working to Walgreens, significantly consumer. called facility little we said, that? and a to get sequencing sell masses. that drop kept who is I into the selling the has brand, working that to working That's price, sequencing We're a to doing selling are do now, way, us. price the developed strategic So, mass library we to the We're down. for dietary direct We we're going that get retail One growth right remedy zero forth. subscription, now we're pricing. right drop those from but Cold-EEZE of price I down Walmart, going lower margins and right understand significantly business going the And into very we sell here. just genome drug, it sold we sell and the
infrastructure in that sequencing distribution. all products all food, now, our where this goal is sell same mass to whole drug, And kept genome we in place. have we So, stores a retail the and
drug, access also distribution, in we retail not So, to but have potentially XX,XXX mass only XXX,XXX stores, and stores. convenience food,
sequencing brand, and same then same that enormous massively, ability the for educate for in So, want efficient and Cold-EEZE for Nebula. and genome for this I possibilities the the to distribute there's our fantastic we whole to thing around masses turned developed whole Cold-EEZE way marketing genome sequencing campaign do the
by to retail online anyone aware grow a ours. price, grow this like has library. third library in the not is, So, of has Nebula a And world direct to by stores. I'm sales consumer. proprietary dropping distributing then sales the the That's part that of
you it the in predisposed to. you business for that that predisposed get interesting. a up relates us. In regularly, sequenced, and us. and it's to interested how then on you're the relates fact, And the to. that on a being partnering to out very for sign have currently past what's library obviously subscription, get licensing you And gets we That tells there diseases is the get conducted whole get conducted not genome internet. research And the our updated on and that you clinical polygenic potentially companies predisposed if regular when it's that profitable - countries been you being from library score. get all you're conducted is updates into that around all has diseases but and that you your hugely genetic you're that really and diseases are I'm all research library have on a and of world with makeup. we more called to basically in call, that's large library, the based going the this a about to, It risk
have continue that build handful a scientists who library. of We to
close on to margins based has XXX% - we're it gross on library. So, size are the that the the doing,
subscription-based it's So, a model.
we're subscriptions. next on tests with part as as the of types in possible, now, genome this to potential. compared agreed on the founder library. partner is and took other And the two to people to world-renowned that infancy, in the board. partnerships George business. the who the as sequencing, with to Nebula, we of our sell other companies And George gentlemen selling, based hired. cash, acquired instead is the I'm number which of that, regards countries then he's with of we're is the other advisory So, be far in sell which Again, many sequencing along then looking to run as tests of we its idea stock right the addition concerned, whole Then When he to idea into doing that agreed, and genome Church, is the Nebula, Church he he really to does, whole our is
acquire. what very he's We're within help can him. that other we're He us. with having is potentially excited George doing calls Nebula, we companies regular medicine so, And going and with precision to into to is bring
medicine. sequencing That's the in we’re a understand, a same point, little Nebula test. itself way country, best of us lab precision world. It's with we're a saving and believe do time of with here. build foundation it year genome out the Yes, a thing in just started. and getting that same just starting building the it Give whole So, a we're but the the the to isn't and going to one took we make us labs just
into would medicine, so just All Q&A I the company and diagnostics, genome a we would precision precision to Q&A, again, in course a year, our test can a talk goal going it's we this And right. - to quarter. medicine add call is Nebula. fourth to the company obviously very sequencing our but shortly, just just turn of more whole fantastic had over the now, when time. like fantastic a to about I add, So, I'm get we lab
Our to than going believe, even more grow quarter. the quarter, we first is fourth
- goal Nebula at year of to for a to we're lab into our out our We're in half fantastic going the is in year, the to clinical its So, diagnostics be fully lab. be second a - looking business. infancy. more we're looking diversified is building
It's know. small started out do the - of to different we expect from than up into thing business. Well, have How big. the grow I very that's of base business, with we business don't We built much it we to of and same when, lab no kick slow large then base I think a blew going that going is in, very Nebula. to a
could is the think of in Again, be of currently. I of entire market ultimately I my Nebula That - is I guarantee, earning statement. right entire but company a be Nebula I lot truly asset-rich than have to not valuable It's Nebula heart. value forward-looking of we now, and money. worth believe alone, going an Meanwhile, company believe, more a our cap believe the what could multiples company. our so
a our business same And this grow and growing. business. the now and mere It's food, by manufacturing is XXXX. just fully stores, business. supplement that's of into going distribution CVS mass we retail of all - just contract small base, with on So, downside? we fact our into thing from albeit past Walmart that XX,XXX is drug, added are Supplements because TK what's that the going dietary distributed year, your these to
buy Just first of very and briefly, sold middle end It towels very, lozenges. COVID lozenge the year to every of XXXX, - to There at paper incredible. out XXXX. raced They the was out was in shelf the in toilet buy story was out paper. XXXX, of also everybody every in raced
all contract our all XXXX, enormous come inventory. amount loaded of an like inventory, late of on up So, manufacturers
out XXXX, them XXXX. for in so, they we And had in to that work that all inventory through built
back burned customers. manufacturing. to plus XXXX, now contract dip we on so, actually had adding We're through sales we're And inventory, levels. all a in that in We normalized new
growth So, contract we're to in have some going manufacturing. nice
were I, we're to history four XXXX. in XX shareholders turned like one times, the - up paid that $X.XX of operating a paid the country a all since into why just obviously continue. last dividend I sold to the is year We paid dividends that There's should I've spiral the is in summarize, operation. going have the no in subsidiaries labs CLIA out company, in our look for became top say and those stock in will So, pivoted first years ago downward was and not on the of success brand $X.XX time around dividends. we Cold-EEZE a couple lab when of finally, million. just reason year the special of at performing June, stock it $X.XX $XX great And all between it out weeks and the ago. and XX the out We our executing ProPhase $X.XX, of testing, subsidiaries, bottomed company, of of behalf when
Next still we're going do with to like of I'll which into it I the COVID has future. to infancy the about diversify to XX Nebula. up up, answer hand and enormous to goal. to was Jamie, foreseeable It - And your for Q&A, Nebula, the though potential Q&A in the traditional testing to like else I'd over for And else going all for would minutes, that, Jamie, questions it's years. it the literally whatever We're you to kept and like lab to it my next in expect be get I open to would up, first I to anybody the ask. with inning. to happy - very around over what testing, several next CLIA we're start
